Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Notes Payables: 2017-2018

  • Organogenesis Holdings' Notes Payables fell 0.06% to $15.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $15.9 million, marking a year-over-year decrease of 0.06%. This contributed to the annual value of $15.9 million for FY2018, which is 0.06% down from last year.
  • Per Organogenesis Holdings' latest filing, its Notes Payables stood at $15.9 million for Q4 2018, which was down 0.06% from $15.9 million recorded in Q4 2017.
  • Organogenesis Holdings' 5-year Notes Payables high stood at $15.9 million for Q4 2017, and its period low was $15.9 million during Q4 2018.
  • Over the past 2 years, Organogenesis Holdings' median Notes Payables value was $15.9 million (recorded in 2017), while the average stood at $15.9 million.
  • Data for Organogenesis Holdings' Notes Payables shows a maximum YoY decreased of 0.06% (in 2018) over the last 5 years.
  • Organogenesis Holdings' Notes Payables (Quarterly) stood at $15.9 million in 2017, then dropped by 0.06% to $15.9 million in 2018.